Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-979-2 | CAS number: 26761-45-5
Endpoint summary
Administrative data
Description of key information
Acute toxicity study data was available for 2,3-epoxypropyl neodecanoate for all three routes of administration: oral, dermal and inhalation. The findings demonstrate that 2,3-epoxypropyl neodecanoate is not acutely toxic by these three routes of administration.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
2,3 -Epoxypropyl neodecanoate had an acute oral LD50 value of > 2000 mg/kg of body weight in rat O.E.C.D. Testing Guideline GLP study. The acute rat dermal LD50 value for 2,3 -epoxypropyl neodecanoate in an O.E.C.D. 402 Testing Guideline GLP study was > 2000 mg/kg of body weight. No mortalities occured at the saturated vapor concentration of 240 mg/m3 (26 ppm) in a rat 4 hr inhalation study. Therefore, the estimated 4 hr LC50 value for 2,3 -epoxypropyl neodecanoate is > 240 mg/m3 (26 ppm). These findings demonstrate that 2,3 -epoxypropyl neodecanoate is not acutely toxic by the oral, dermal and inhalation routes of administration.
Justification for selection of acute toxicity – oral endpoint
REACH Annex VII requirement.
Justification for selection of acute toxicity – dermal endpoint
REACH Annex VIIi requirement.
Justification for classification or non-classification
Study data demonstrate that 2,3 -epoxypropyl neodecanoate is not acutely toxic by the oral, dermal and inhalation routes of administration. Therefore, Classification for acute toxicity is not required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
